ZYRTEC ALLERGY Drug Patent Profile
✉ Email this page to a colleague
When do Zyrtec Allergy patents expire, and when can generic versions of Zyrtec Allergy launch?
Zyrtec Allergy is a drug marketed by J And J Consumer Inc and is included in two NDAs.
The generic ingredient in ZYRTEC ALLERGY is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and fifty-eight suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zyrtec Allergy
A generic version of ZYRTEC ALLERGY was approved as cetirizine hydrochloride by PADAGIS US on June 17th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZYRTEC ALLERGY?
- What are the global sales for ZYRTEC ALLERGY?
- What is Average Wholesale Price for ZYRTEC ALLERGY?
Summary for ZYRTEC ALLERGY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 119 |
| Clinical Trials: | 30 |
| Patent Applications: | 2,616 |
| What excipients (inactive ingredients) are in ZYRTEC ALLERGY? | ZYRTEC ALLERGY excipients list |
| DailyMed Link: | ZYRTEC ALLERGY at DailyMed |
Recent Clinical Trials for ZYRTEC ALLERGY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Emory University | Phase 4 |
| Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division | Phase 1 |
| Indiana University | Phase 4 |
Pharmacology for ZYRTEC ALLERGY
| Drug Class | Histamine-1 Receptor Antagonist |
| Mechanism of Action | Histamine H1 Receptor Antagonists |
US Patents and Regulatory Information for ZYRTEC ALLERGY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J And J Consumer Inc | ZYRTEC ALLERGY | cetirizine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 022578-001 | Sep 3, 2010 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| J And J Consumer Inc | ZYRTEC ALLERGY | cetirizine hydrochloride | TABLET;ORAL | 019835-003 | Nov 16, 2007 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| J And J Consumer Inc | ZYRTEC ALLERGY | cetirizine hydrochloride | TABLET;ORAL | 019835-004 | Nov 16, 2007 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZYRTEC ALLERGY
See the table below for patents covering ZYRTEC ALLERGY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 154078 | ⤷ Sign Up | |
| Poland | 234935 | ⤷ Sign Up | |
| Poland | 239687 | ⤷ Sign Up | |
| Hong Kong | 86485 | 2-(4-DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACIDS AND THEIR AMIDES,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZYRTEC ALLERGY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0058146 | SPC/GB01/052 | United Kingdom | ⤷ Sign Up | SPC/GB01/052:, EXPIRES: 20070205 |
| 0663828 | C300085 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103 |
| 0058146 | 2001C/045 | Belgium | ⤷ Sign Up | PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
